Organization
Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS
2 abstracts
Abstract
Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.Org: NYU Langone Health, New York, NY, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Augusta University, Augusta, GA, Bio-Path Holdings, Inc., Bellaire, TX,
Abstract
Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.Org: Cardio-Oncology Center of Excellence, Washington University School of Medicine, St. Louis, MO, Heart and Vascular Institute, Penn State Hershey Medical Center, Hershey, PA, Jazz Pharmaceuticals, Philadelphia, PA, Jazz Pharmaceuticals, Palo Alto, CA, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS,